Literature DB >> 19012506

Recent advances in biliary atresia: prospects for novel therapies.

Barbara A Haber1, Jessi Erlichman, Kathleen M Loomes.   

Abstract

BACKGROUND: Biliary atresia (BA) is a progressive fibro-obliterative disease of the extrahepatic biliary tree that presents with biliary obstruction before 2 months of age. Untreated BA is a uniformly fatal disease and even with our current therapies only 50% of children with BA will be transplant-free by 2 years of age. Despite descriptions of this disorder dating back to the 1800s our current therapies are palliative. They focus on prompt diagnosis, supportive nutritional care and interventions for sequelae.
OBJECTIVE: To present the literature supporting current treatment strategies and potential future therapies.
METHOD: Each of the aspects of care is described and the literature about nuances of care is provided.
CONCLUSION: Therapies will not improve outcomes until novel treatments are introduced, such as those suggested, which may intervene in the inflammatory or fibrotic steps of the disease process.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19012506     DOI: 10.1517/13543780802514120

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  3 in total

Review 1.  Biliary disease in children.

Authors:  Matthew Goldman; Thomas Pranikoff
Journal:  Curr Gastroenterol Rep       Date:  2011-04

2.  Liver and portal histopathological correlation with age and survival in extra hepatic biliary atresia.

Authors:  Shilpa Sharma; Prasenjit Das; S Dattagupta; Lalit Kumar; Devendra K Gupta
Journal:  Pediatr Surg Int       Date:  2011-05       Impact factor: 1.827

3.  Bone marrow mononuclear stem cell infusion improves biochemical parameters and scintigraphy in infants with biliary atresia.

Authors:  Shilpa Sharma; Lalit Kumar; Sujata Mohanty; Rakesh Kumar; S Datta Gupta; Devendra K Gupta
Journal:  Pediatr Surg Int       Date:  2011-01       Impact factor: 1.827

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.